Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP283631.RAuguc31Gvof3LlzlqlqapYhdcUcj0nuJDxB-0IJnyulI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP283631.RAuguc31Gvof3LlzlqlqapYhdcUcj0nuJDxB-0IJnyulI130_assertion type Assertion NP283631.RAuguc31Gvof3LlzlqlqapYhdcUcj0nuJDxB-0IJnyulI130_head.
- NP283631.RAuguc31Gvof3LlzlqlqapYhdcUcj0nuJDxB-0IJnyulI130_assertion description "[The only difference is that patients with PKD2 mutations run a milder course compared to PKD1 carriers, with an average 10-20 years later age of onset and lower probability to reach end-stage-renal failure.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP283631.RAuguc31Gvof3LlzlqlqapYhdcUcj0nuJDxB-0IJnyulI130_provenance.
- NP283631.RAuguc31Gvof3LlzlqlqapYhdcUcj0nuJDxB-0IJnyulI130_assertion evidence source_evidence_literature NP283631.RAuguc31Gvof3LlzlqlqapYhdcUcj0nuJDxB-0IJnyulI130_provenance.
- NP283631.RAuguc31Gvof3LlzlqlqapYhdcUcj0nuJDxB-0IJnyulI130_assertion SIO_000772 11438989 NP283631.RAuguc31Gvof3LlzlqlqapYhdcUcj0nuJDxB-0IJnyulI130_provenance.
- NP283631.RAuguc31Gvof3LlzlqlqapYhdcUcj0nuJDxB-0IJnyulI130_assertion wasDerivedFrom befree-20140225 NP283631.RAuguc31Gvof3LlzlqlqapYhdcUcj0nuJDxB-0IJnyulI130_provenance.
- NP283631.RAuguc31Gvof3LlzlqlqapYhdcUcj0nuJDxB-0IJnyulI130_assertion wasGeneratedBy ECO_0000203 NP283631.RAuguc31Gvof3LlzlqlqapYhdcUcj0nuJDxB-0IJnyulI130_provenance.